Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
V Noronha, VM Patil, A Joshi, N Menon… - Journal of Clinical …, 2020 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> Standard first-line therapy for
EGFR-mutant advanced non–small-cell lung cancer (NSCLC) is an epidermal growth factor …
EGFR-mutant advanced non–small-cell lung cancer (NSCLC) is an epidermal growth factor …
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
V Noronha, VM Patil, A Joshi… - Journal of clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose Standard first-line therapy for EGFR-mutant advanced non-small-cell lung cancer
(NSCLC) is an epidermal growth factor receptor (EGFR)-directed oral tyrosine kinase …
(NSCLC) is an epidermal growth factor receptor (EGFR)-directed oral tyrosine kinase …
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.
V Noronha, VM Patil, A Joshi, N Menon… - Journal of Clinical …, 2019 - europepmc.org
Purpose Standard first-line therapy for EGFR-mutant advanced non-small-cell lung cancer
(NSCLC) is an epidermal growth factor receptor (EGFR)-directed oral tyrosine kinase …
(NSCLC) is an epidermal growth factor receptor (EGFR)-directed oral tyrosine kinase …